Cargando…

Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?

Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms th...

Descripción completa

Detalles Bibliográficos
Autores principales: Peltonen, Juhana, Johansson, Edvard, Wincent, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496259/
https://www.ncbi.nlm.nih.gov/pubmed/32567214
http://dx.doi.org/10.1002/hec.4120
_version_ 1783583058077679616
author Peltonen, Juhana
Johansson, Edvard
Wincent, Joakim
author_facet Peltonen, Juhana
Johansson, Edvard
Wincent, Joakim
author_sort Peltonen, Juhana
collection PubMed
description Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms through medication. Although this development has led to many positive outcomes, the broader societal implications are still poorly understood. In particular, person‐level studies suggest that ADHD‐like behavior may possess some advantages for engaging in entrepreneurship and the initiation of new businesses, which is considered a key activity for economic development. Using recent panel data from 11 countries and one special administrative region (SAR), we investigate if the increasing use of ADHD medication in adults is associated with an unintended outcome of reducing entrepreneurship. We find that a roughly one unit increase in the prevalence of adult ADHD medication is associated with a one unit decrease in limited liability company registrations per working age population. In practical terms, the effect of a one within‐country/SAR standard deviation increase of adult ADHD medication prevalence corresponds to a decrease in new business formation of 20% of its mean in the sample.
format Online
Article
Text
id pubmed-7496259
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74962592020-09-25 Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship? Peltonen, Juhana Johansson, Edvard Wincent, Joakim Health Econ Health Economics Letters Attention‐deficit hyperactivity disorder (ADHD) is a highly inheritable condition with a rather stable prevalence over time and geography, and it is associated with a broad range of negative life outcomes. Increasing knowledge on the condition has led to a growing trend of dampening ADHD symptoms through medication. Although this development has led to many positive outcomes, the broader societal implications are still poorly understood. In particular, person‐level studies suggest that ADHD‐like behavior may possess some advantages for engaging in entrepreneurship and the initiation of new businesses, which is considered a key activity for economic development. Using recent panel data from 11 countries and one special administrative region (SAR), we investigate if the increasing use of ADHD medication in adults is associated with an unintended outcome of reducing entrepreneurship. We find that a roughly one unit increase in the prevalence of adult ADHD medication is associated with a one unit decrease in limited liability company registrations per working age population. In practical terms, the effect of a one within‐country/SAR standard deviation increase of adult ADHD medication prevalence corresponds to a decrease in new business formation of 20% of its mean in the sample. John Wiley and Sons Inc. 2020-06-22 2020-09 /pmc/articles/PMC7496259/ /pubmed/32567214 http://dx.doi.org/10.1002/hec.4120 Text en © 2020 The Authors. Health Economics published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Health Economics Letters
Peltonen, Juhana
Johansson, Edvard
Wincent, Joakim
Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title_full Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title_fullStr Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title_full_unstemmed Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title_short Does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
title_sort does attention‐deficit hyperactivity disorder medication reduce entrepreneurship?
topic Health Economics Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496259/
https://www.ncbi.nlm.nih.gov/pubmed/32567214
http://dx.doi.org/10.1002/hec.4120
work_keys_str_mv AT peltonenjuhana doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship
AT johanssonedvard doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship
AT wincentjoakim doesattentiondeficithyperactivitydisordermedicationreduceentrepreneurship